Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage (AMB-WEI-1052-I)
Single- Arm Trial to Identify Potential Markers Underlying Variability in Response to Omalizumab (Xolair®) Treatment in Atopic Dermatitis
Sponsor: Technical University of Munich
A PHASE2 clinical study on Atopic Dermatitis and Atopic Eczema, this trial is completed. The trial is conducted by Technical University of Munich and has accumulated 7 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Technical University of Munich
For direct contact, visit the study record on ClinicalTrials.gov .